What the evidence actually supports for people without diabetes
Aggiornato 2026-08-07
Questa guida non è ancora tradotta nella tua lingua, quindi è mostrata in inglese.
Risposta breve
Is a CGM worth it if you do not have diabetes?
It depends which non-diabetic you are. If you have prediabetes or clear risk factors, a sensor can make an intervention that is already proven — changing what you eat and how much you move — more concrete. If you are metabolically healthy, there is no good evidence that wearing one improves any health outcome, and popular claims about glucose spikes outrun what has been shown.
Come leggere le etichette dell’evidenza
Ogni affermazione di questa pagina porta un’etichetta che indica quanto peso può reggere. Descrive la solidità del risultato, non il prestigio della rivista.
- Evidenza solidaUn grande studio randomizzato, una coorte seguita a lungo, o la concordanza di più studi.
- Evidenza preliminareReale, ma sottile — piccolo, breve, osservazionale o non ancora replicato.
- ControversoRicercatori competenti sono apertamente in disaccordo. Non scegliamo noi da che parte stare.
Where the evidence is strong
In diabetes, the case is settled enough to be written into clinical targets. Time spent in the 3.9–10.0 mmol/L range is strongly associated with the risk of microvascular complications, and international consensus targets exist for it.
None of that transfers automatically to a person without diabetes. The targets were derived in diabetic populations, and there is no validated time-in-range target for anyone else.
Che cosa dicono le prove
In people with diabetes, each 10-percentage-point reduction in time in range was associated with a 64% higher rate of retinopathy progression and a 40% higher rate of developing microalbuminuria.1
Evidenza solida
Consensus time-in-range targets are defined for diabetic populations; no equivalent validated target exists for people without diabetes.2
Evidenza solida
Where the evidence is reasonable
In prediabetes, the intervention with proven benefit is behavioural, not technological. A large randomised trial cut progression to type 2 diabetes by more than half using weight loss and physical activity — no sensor involved.
That is the honest framing for a CGM here: a biofeedback tool that may help someone carry out an intervention already known to work, inside a structured programme. It is not itself the intervention, and it has not been shown to add to one.
Che cosa dicono le prove
A lifestyle programme targeting 7% weight loss and 150 minutes of activity a week reduced the incidence of type 2 diabetes by 58%, and metformin by 31%, in people at high risk.3
Evidenza solida
Lifestyle modification in prediabetes is associated with a 40–70% relative reduction in diabetes risk.4
Evidenza solida
Where the evidence is thin, and the marketing is not
Search for glucose spikes and you will find a large body of confident material about energy, mood, sleep, ageing and cancer risk. A review that set that material side by side with the peer-reviewed literature found claims in the popular sources that the medical literature does not support.
What the medical literature does describe — endothelial dysfunction, oxidative stress, inflammation following glucose excursions — is mechanistic, and the plausible harms attach to frequent spikes sustained over long periods rather than to any one meal. Meanwhile monitoring studies show that normoglycaemic people regularly reach ranges labelled prediabetic, which makes "I saw a spike" a weak basis for concern.
Che cosa dicono le prove
A scoping review comparing popular and peer-reviewed sources on glucose spikes found the popular sources asserting effects — on cancer risk, mental health, energy, mood and sleep — that the medical literature did not support.5
Evidenza preliminare
Glucose readings in the prediabetic range occur regularly in people classed as normoglycaemic, so an isolated high reading is weak evidence of a problem.6
Evidenza preliminare
The claim we will not make
One popular idea is that measuring your own glucose response lets you pick the diet that suits your physiology. It is appealing, and it is not established. A randomised trial of 609 adults compared healthy low-fat against healthy low-carbohydrate diets and found no meaningful difference in weight change — and, importantly, that baseline insulin secretion did not identify who would do better on which.
We sell nothing by saying this. We say it because the alternative is to imply a personalisation benefit that a well-run trial specifically looked for and did not find.
Che cosa dicono le prove
In a 12-month randomised trial, healthy low-fat and healthy low-carbohydrate diets produced no significant difference in weight loss, and baseline insulin secretion did not predict which diet worked better for whom.7
Evidenza solida
Domande frequenti
- Will a CGM help me lose weight?
- No trial has shown that wearing a CGM causes weight loss in people without diabetes. The behaviours a sensor might encourage — eating differently, moving more — have strong evidence behind them on their own.
- Are glucose spikes dangerous for healthy people?
- The mechanistic literature describes real effects of glucose excursions on blood vessels, but the harms plausibly attach to frequent spikes over long periods, not to isolated ones. Popular sources go considerably further than the evidence does.
- So why does this site sell CGMs?
- We earn commission on links, and we would rather tell you the evidence is thin and lose the sale than the reverse. If you are metabolically healthy and curious, that is a legitimate reason to buy one — but curiosity is what you are buying, not a health outcome.
Bibliografia
- 1.Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL (2019). Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 10.2337/dc18-1444
- 2.Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. (2019). Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 10.2337/dci19-0028
- 3.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (Diabetes Prevention Program Research Group) (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 10.1056/NEJMoa012512
- 4.Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M (2012). Prediabetes: a high-risk state for diabetes development. The Lancet. 10.1016/S0140-6736(12)60283-9
- 5.Avner S, Robbins T (2025). A Scoping Review of Glucose Spikes in People Without Diabetes: Comparing Insights from Grey Literature and Medical Research. Clinical Medicine Insights: Endocrinology and Diabetes. 10.1177/11795514251381409
- 6.Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M (2018). Glucotypes reveal new patterns of glucose dysregulation. PLoS Biology. 10.1371/journal.pbio.2005143
- 7.Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, Desai M, King AC (2018). Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA. 10.1001/jama.2018.0245